Enhancing the potency and specificity of engineered T cells for cancer treatment

Keyphrases

• Cancer Treatment 100%
• Tumor Site 100%
• Engineered T Cells 100%
• Chimeric Antigen Receptor T Cells (CAR-T) 66%
• T Cells 66%
• Tumor 33%
• Interleukin-13 (IL-13) 33%
• Antitumor Effect 33%
• Physiologic 33%
• Interleukin-10 33%
• Tumor Response 33%
• Expression Pattern 33%
• Adoptive Transfer 33%
• Safety Profile 33%
• Antitumor Efficacy 33%
• Pancreatic Cancer 33%
• Paucity 33%
• Costimulation 33%
• Proof of Concept Study 33%
• Tumor Selectivity 33%
• Refractory Disease 33%
• Endodomain 33%
• Engineering Approach 33%
• Genetically Modified T Cells 33%
• Cell-responsive 33%
• Programmed Death-ligand 1 (PD-L1) 33%
• Inhibitory Molecules 33%
• Prostate Stem Cell Antigen 33%
• T Cell Signaling 33%
• Immunosuppressive Cytokines 33%
• Off-target Toxicity 33%

Medicine and Dentistry

• Neoplasm 100%
• T Cell 100%
• Cancer Therapy 100%
• Receptor 42%
• Cytokine 28%
• Diseases 14%
• Pancreas Cancer 14%
• Chimeric Antigen Receptor 14%
• Adoptive Transfer 14%
• Immunosuppressive Drug 14%
• Programmed Death-Ligand 1 14%
• T-Cell Signaling 14%
• Prostate Stem Cell Antigen 14%

Biochemistry, Genetics and Molecular Biology

• T Cell 100%
• Cytokine 40%
• Stem Cell 20%
• Signal Transduction 20%
• Chimeric Antigen Receptor 20%
• Transgenics 20%
• PD-L1 20%